Journal article · 2022 · Open access

Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy

Jing Gao, Bo Hou, Qiwen Zhu, Lei Yang, Xingyu Jiang, Zhifeng Zou, Xutong Li, Tianfeng Xu, Mingyue Zheng, Yi‐Hung Chen, Zhiai Xu, Huixiong Xu and 1 more

Nature Communications, 13(1), 4318 · Published 26 July 2022 · DOI 10.1038/s41467-022-32050-4

Open PDFView at the publisherCite this paper

In brief

“Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy” is a 2022 journal article by Jing Gao and 12 co-authors, published in Nature Communications. OpenAlex counts 261 citations as of 20 November 2026, which puts it in the top 3% of works published in 2022 by citations. It is open access under a CC BY licence: the full text is free to read at Nature Communications.

Citations
261
Most cited in
2026 (93)
Field-weighted impact
11.60
References
52
Authors
13

Abstract

PROteolysis TArgeting Chimeras (PROTACs) has been exploited to degrade putative protein targets. However, the antitumor performance of PROTACs is impaired by their insufficient tumour distribution. Herein, we present de novo designed polymeric PROTAC (POLY-PROTAC) nanotherapeutics for tumour-specific protein degradation. The POLY-PROTACs are engineered by covalently grafting small molecular PROTACs onto the backbone of an amphiphilic diblock copolymer via the disulfide bonds. The POLY-PROTACs self-assemble into micellar nanoparticles and sequentially respond to extracellular matrix metalloproteinase-2, intracellular acidic and reductive tumour microenvironment. The POLY-PROTAC NPs are further functionalized with azide groups for bioorthogonal click reaction-amplified PROTAC delivery to the tumour tissue. For proof-of-concept, we demonstrate that tumour-specific BRD4 degradation with the bioorthogonal POLY-PROTAC nanoplatform combine with photodynamic therapy efficiently regress tumour xenografts in a mouse model of MDA-MB-231 breast cancer. This study suggests the potential of the POLY-PROTACs for precise protein degradation and PROTAC-based cancer therapy.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Gao, J., Hou, B., Zhu, Q., Yang, L., Jiang, X., Zou, Z., Li, X., Xu, T., Zheng, M., Chen, Y., Xu, Z., Xu, H., & Yu, H. (2022). Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nature Communications, 13(1), 4318. https://doi.org/10.1038/s41467-022-32050-4

MLA 9

Gao, Jing, et al. “Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.” Nature Communications, vol. 13, no. 1, 2022, p. 4318. https://doi.org/10.1038/s41467-022-32050-4.

Chicago

Gao, Jing, Bo Hou, Qiwen Zhu, Lei Yang, Xingyu Jiang, Zhifeng Zou, Xutong Li, et al. 2022. “Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.” Nature Communications 13 (1): 4318. https://doi.org/10.1038/s41467-022-32050-4.

Harvard

Gao, J. et al. (2022) ‘Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy’, Nature Communications, 13(1), p. 4318. doi:10.1038/s41467-022-32050-4.

IEEE

J. Gao et al., “Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy,” Nature Communications, vol. 13, no. 1, p. 4318, 2022, doi: 10.1038/s41467-022-32050-4.

BibTeX

@article{gao2022engineered,
  title     = {{Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy}},
  author    = {Gao, Jing and Hou, Bo and Zhu, Qiwen and Yang, Lei and Jiang, Xingyu and Zou, Zhifeng and Li, Xutong and Xu, Tianfeng and Zheng, Mingyue and Chen, Yi‐Hung and Xu, Zhiai and Xu, Huixiong and Yu, Haijun},
  journal   = {Nature Communications},
  year      = {2022},
  volume    = {13},
  number    = {1},
  pages     = {4318},
  doi       = {10.1038/s41467-022-32050-4},
  url       = {https://doi.org/10.1038/s41467-022-32050-4}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Citations by year

YearCitationsShare of the best year
202255
20233737
20246161
20256565
20269393

Its field-weighted citation impact is 11.60: it has been cited 11.60 times as often as the average work of the same field, type and year (1.00 is the world average).

Topic and keywords

Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors

  • PROTACs
  • bioorthogonal click chemistry
  • micellar self-assembly
  • tumor microenvironment
  • BRD4 degradation
  • photodynamic therapy
  • breast cancer
  • nanotherapeutics

Work with this paper

Most-cited papers in Biochemistry, Genetics and Molecular Biology

All highly cited Biochemistry, Genetics and Molecular Biology papers

Questions about this paper

How do I cite this paper in APA style?

Gao, J., Hou, B., Zhu, Q., Yang, L., Jiang, X., Zou, Z., Li, X., Xu, T., Zheng, M., Chen, Y., Xu, Z., Xu, H., & Yu, H. (2022). Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy. Nature Communications, 13(1), 4318. https://doi.org/10.1038/s41467-022-32050-4

How many times has this paper been cited?

261 times, according to OpenAlex on 20 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

Yes. It is open access at Nature Communications: sign in and open the PDF from this page.

Who wrote this paper?

Jing Gao, Bo Hou, Qiwen Zhu, Lei Yang, Xingyu Jiang, Zhifeng Zou, Xutong Li, Tianfeng Xu, Mingyue Zheng, Yi‐Hung Chen, Zhiai Xu, Huixiong Xu and 1 more.

What is the DOI of this paper?

10.1038/s41467-022-32050-4, permanently at https://doi.org/10.1038/s41467-022-32050-4. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 20 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.